New Diagnostic Test for Pancreatic Cancer Is Based on the Differential Expression of Select miRNAs in Plasma and Bile
|
By LabMedica International staff writers Posted on 10 Nov 2014 |
|
A panel of microRNA (miRNA) biomarkers was assembled from the pool of miRNAs present in the blood of most pancreatic cancer patients that may serve as a diagnostic tool and an indicator of the disease’s aggressiveness.
Pancreatic cancer is the fourth most common cause of cancer death in the Western world. The prognosis is poor, with one- and five-year survival rates of only 20% and 6%, respectively. Therefore, markers of the disease that could help with early diagnosis are needed to improve the prognosis. Statistics from the [US] National Cancer Institute (Bethesda, MD, USA) show that only about 6% of people with pancreatic cancer survive more than five years after diagnosis. In 2013 an estimated 45,220 new cases of pancreatic cancer were expected to be diagnosed with more than 38,460 of the cases being fatal.
MiRNAs are snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.
Investigators at Indiana University (Indianapolis, USA) determined miRNA levels in blood or bile obtained from 215 patients with pancreatic ductal adenocarcinoma (PDAC) or from controls. Panels were derived from the differential expression of 10 candidate miRNAs in the samples. MiRNAs that had excellent accuracy for inclusion in regression models were selected. Total RNA was isolated from samples using Trizol-LS (Life Technologies; Carlsbad, CA, USA). Complementary DNA was generated using 10 ng of RNA in conjunction with miRNA-10b, -21, -30c, -106b, -132, -155, -181a, -181b, -196a, -212, or -425-5p reverse transcription primers and a miRNA reverse transcription kit (Life Technologies). Quantitative PCR was performed for each miRNA using Taqman (Life Technologies) miRNA expression assay reagents.
Results revealed that increased expression of miRNA-10b, -155, and -106b in plasma appeared to be highly accurate for diagnosing pancreatic cancer.
Senior author Dr. Murray Korc, professor of cancer research at Indiana University, said, “This is a new finding that extends previous knowledge in this field. The key new feature here is that there is a panel of microRNAs that can be measured accurately in the plasma component of blood to determine if a patient has pancreatic cancer. It may be possible to use a blood test to screen individuals who are at high risk for developing pancreatic cancer. We are planning to conduct such studies. It will be important to identify additional markers and to assess how useful a panel of such markers would be for the early diagnosis of this cancer. Based on our findings, this test could also be useful to differentiate between pancreatic cancer and chronic pancreatitis.”
The study was published in the October 28, 2014, online edition of the American Journal of Gastroenterology.
Related Links:
National Cancer Institute
Indiana University
Life Technologies
Pancreatic cancer is the fourth most common cause of cancer death in the Western world. The prognosis is poor, with one- and five-year survival rates of only 20% and 6%, respectively. Therefore, markers of the disease that could help with early diagnosis are needed to improve the prognosis. Statistics from the [US] National Cancer Institute (Bethesda, MD, USA) show that only about 6% of people with pancreatic cancer survive more than five years after diagnosis. In 2013 an estimated 45,220 new cases of pancreatic cancer were expected to be diagnosed with more than 38,460 of the cases being fatal.
MiRNAs are snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.
Investigators at Indiana University (Indianapolis, USA) determined miRNA levels in blood or bile obtained from 215 patients with pancreatic ductal adenocarcinoma (PDAC) or from controls. Panels were derived from the differential expression of 10 candidate miRNAs in the samples. MiRNAs that had excellent accuracy for inclusion in regression models were selected. Total RNA was isolated from samples using Trizol-LS (Life Technologies; Carlsbad, CA, USA). Complementary DNA was generated using 10 ng of RNA in conjunction with miRNA-10b, -21, -30c, -106b, -132, -155, -181a, -181b, -196a, -212, or -425-5p reverse transcription primers and a miRNA reverse transcription kit (Life Technologies). Quantitative PCR was performed for each miRNA using Taqman (Life Technologies) miRNA expression assay reagents.
Results revealed that increased expression of miRNA-10b, -155, and -106b in plasma appeared to be highly accurate for diagnosing pancreatic cancer.
Senior author Dr. Murray Korc, professor of cancer research at Indiana University, said, “This is a new finding that extends previous knowledge in this field. The key new feature here is that there is a panel of microRNAs that can be measured accurately in the plasma component of blood to determine if a patient has pancreatic cancer. It may be possible to use a blood test to screen individuals who are at high risk for developing pancreatic cancer. We are planning to conduct such studies. It will be important to identify additional markers and to assess how useful a panel of such markers would be for the early diagnosis of this cancer. Based on our findings, this test could also be useful to differentiate between pancreatic cancer and chronic pancreatitis.”
The study was published in the October 28, 2014, online edition of the American Journal of Gastroenterology.
Related Links:
National Cancer Institute
Indiana University
Life Technologies
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Latest Pathology News
- Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
- AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
- AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps
- AI Pre-Screening Helps Identify Lung Cancer Cases for Additional Biomarker Testing
- AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
- Updated Digital Pathology Platform Expands AI Integration for Cancer Diagnosis
- Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
- AI Histopathology Tool Distinguishes Ewing Sarcoma for Diagnosis
- Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
- Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
- Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts
- New AI Model Maps Where Glioblastoma Could Return After Surgery
- Simple Test Could Reduce the Need for Invasive Uterine Cancer Checks
- Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
- Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
- Machine Learning Cytology Tool Improves Cancer Cell Identification
Channels
Clinical Chemistry
view channel
Point-of-Care Blood Biomarker Test Detects Brain Injury Missed by CT
Traumatic brain injury remains difficult to assess in emergency settings because some patients continue to have symptoms despite normal computed tomography findings. Approximately 2.8 million people in the U.... Read more
Daily Blood Testing May Help Guide Earlier Antibiotic Stopping in Sepsis
Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more
Molecular Diagnostics
view channel
Molecular Vaginitis Panel Gains FDA Clearance and CLIA Waiver for Point-of-Care Use
Vaginitis affects most women at least once in their lifetime and can cause painful, disruptive symptoms. Common causes include bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis, reflecting... Read more
AI Tool Predicts Immunotherapy Response Using Tumor Senescence Signals
Patients receiving the same cancer immunotherapy can have markedly different outcomes, with some showing little or no response. Identifying these patients earlier could reduce the costs of ineffective... Read more
Hematology
view channel
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read more
Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
Severe blood loss and inadequate tissue oxygenation are leading causes of preventable death after traumatic injury. Blood products are essential in trauma care, but cold-chain storage, short shelf life,... Read more
Immunology
view channel
Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more
Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more
Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more
Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read moreMicrobiology
view channel
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read more
Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
Sepsis and severe infections are difficult to treat because patients with similar clinical presentations may have very different underlying immune responses. Corticosteroids are commonly used in severe... Read more
Technology
view channel
New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows
Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Industry
view channel
Hologic and Inpeco Partner to Advance Molecular Laboratory Automation in Europe
Hologic, Inc. (Marlborough, MA, USA) and Inpeco S.A. (Novazzano, Switzerland) have signed a co-marketing partnership in Europe for Inpeco’s recently launched FlexLab X automation solution and Hologic’s... Read more
Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection
Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Alzheimer’s Progression Blood Test Gains U.S. Patent Ahead of Planned Launch
Alzheimer’s disease is the most common cause of dementia, accounting for an estimated 60–70% of cases worldwide. Its progressive effects on memory, thinking, behavior, and daily functioning underscore... Read more